搜索医生

Paul M. McKie, M.D.

  1. Cardiologist
  2. Echocardiographer
  3. Internist
预约门诊

出版物

  1. Hubers SA, Benike SL, Johnson BK, McKie PM, Scott C, Chen HH. Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial. Circ Heart Fail. 2024 Nov 8; e011761 Epub 2024 Nov 08
    View PubMed
  2. Ma X, McKie PM, Iyer SR, Scott C, Bailey K, Johnson BK, Benike SL, Chen H, Miller WL, Cabassi A, Burnett JC Jr, Cannone V. MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease. JACC Basic Transl Sci. 2024 Jan; 9 (1):18-29 Epub 2023 Nov 01
    View PubMed
  3. O'Sullivan CC, Higgins AS, Alkurashi AK, Ahluwalia V, Taraba JL, McKie PM, Kamath PS, Iyer VN, Haddad TC. Hepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series. Front Oncol. 2024; 14:1434492 Epub 2024 Oct 21
    View PubMed
  4. Vinnakota S, Adel FW, McKie PM, Scott CG, Chen HH. The Cardiorenal Effects of Chronic Phosphodiesterase-V Inhibition in Preclinical Diastolic Dysfunction (Stage B Heart Failure). J Card Fail. 2023 Oct; 29 (10):1461-1465 Epub 2023 June 07
    View PubMed
  5. Harmon DM, AbouEzzeddine OF, McKie PM, Scott CG, Saenger AK, Jaffe AS. Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. Biomarkers. 2021 Nov; 26 (7):639-646 Epub 2021 July 29
    View PubMed
  6. AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 1; 6 (11):1267-1274
    View PubMed
  7. Kashou AH, Medina-Inojosa JR, Noseworthy PA, Rodeheffer RJ, Lopez-Jimenez F, Attia IZ, Kapa S, Scott CG, Lee AT, Friedman PA, McKie PM. Artificial Intelligence-Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population. Mayo Clin Proc. 2021 Oct; 96 (10):2576-2586 Epub 2021 June 10
    View PubMed
  8. Wan SH, McKie PM, Slusser JP, Burnett JC Jr, Hodge DO, Chen HH. Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiol Rep. 2021 Aug; 9 (16):e14974
    View PubMed
  9. Cannone V, Ledwidge M, Watson C, McKie PM, Burnett JC Jr, McDonald K. STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure. JACC Basic Transl Sci. 2021 Jun; 6 (6):497-504 Epub 2021 June 16
    View PubMed
  10. Young NP, Burkholder DB, Philpot LM, McKie PM, Ebbert JO. Synchronous neurology-primary care collaboration in a medical home. Neurol Clin Pract. 2020 Oct; 10 (5):388-395
    View PubMed
  11. McKie PM, Kor DJ, Cook DA, Kessler ME, Carter RE, Wilson PM, Pencille LJ, Hickey BC, Chaudhry R. Computerized Advisory Decision Support for Cardiovascular Diseases in Primary Care: A Cluster Randomized Trial. Am J Med. 2020 Jun; 133 (6):750-756.e2 Epub 2019 Dec 18
    View PubMed
  12. Wan SH, Torres-Courchoud I, McKie PM, Slusser JP, Redfield MM, Burnett JC Jr, Hodge DO, Chen HH. Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic Transl Sci. 2019 Dec; 4 (8):962-972 Epub 2019 Dec 23
    View PubMed
  13. Agor JK, Sir MY, Pasupathy KS, Foley DA, Scott CG, Elrashidi MY, Young NP, McKie PM. Getting to the Heart of the Matter: A Triage Model to Improve Utilization of Cardiology Consultative Services. Mayo Clin Proc Innov Qual Outcomes. 2019 Dec; 3 (4):476-482 Epub 2019 Oct 22
    View PubMed
  14. McKie P, Bundrick JB. Clinical Pearls in Cardiology 2019. Dis Mon. 2019 Nov; 65 (11):100859 Epub 2019 June 24
    View PubMed
  15. Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, Pellikka PA, Enriquez-Sarano M, Noseworthy PA, Munger TM, Asirvatham SJ, Scott CG, Carter RE, Friedman PA. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019 Jan; 25 (1):70-74 Epub 2019 Jan 07
    View PubMed
  16. Wan SH, McKie PM, Bois JP. A Contemporary Systematic Approach to Assessing the Patient with Heart Failure with Reduced Ejection Fraction: Multimodal Noninvasive and Invasive Evaluation. Cardiol Res Pract. 2019; 2019:3039740 Epub 2019 Sept 11
    View PubMed
  17. Young NP, Elrashidi MY, McKie PM, Ebbert JO. Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia. 2018 Oct; 38 (12):1841-1848 Epub 2018 Feb 12
    View PubMed
  18. Grodin JL, Mullens W, Dupont M, Taylor DO, McKie PM, Starling RC, Testani JM, Tang WHW. Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. Int J Cardiol. 2018 Feb 1; 252:112-116
    View PubMed
  19. Kessler ME, Carter RE, Cook DA, Kor DJ, McKie PM, Pencille LJ, Scheitel MR, Chaudhry R. Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial. BMJ Open. 2017 Dec 4; 7 (12):e019087 Epub 2017 Dec 04
    View PubMed
  20. Elrashidi MY, Philpot LM, Young NP, Ramar P, Swanson KM, McKie PM, Crane SJ, Ebbert JO. Effect of integrated community neurology on utilization, diagnostic testing, and access. Neurol Clin Pract. 2017 Aug; 7 (4):306-315
    View PubMed
  21. AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2017 Feb 18; 6 (2)
    View PubMed
  22. Carter RE, McKie PM, Storlie CB. The Fragility Index: a P-value in sheep's clothing? Eur Heart J 2017 Feb 1; 38 (5):346-348
    View PubMed
  23. AbouEzzeddine OF, McKie PM, Scott CG, Rodeheffer RJ, Chen HH, Michael Felker G, Jaffe AS, Burnett JC, Redfield MM. Biomarker-based risk prediction in the community. Eur J Heart Fail. 2016 Nov; 18 (11):1342-1350
    View PubMed
  24. Wan SH, McKie PM, Schirger JA, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH. Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure). JACC Heart Fail. 2016 Jul; 4 (7):539-547 Epub 2016 Feb 10
    View PubMed
  25. McKie PM, Schirger JA, Benike SL, Harstad LK, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH. Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail. 2016 Apr; 18 (4):433-41 Epub 2016 Jan 24
    View PubMed
  26. Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension. 2015 Jun; 65 (6):1187-94 Epub 2015 Apr 20
    View PubMed
  27. McKie PM, Burnett JC Jr. Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure. Curr Heart Fail Rep. 2015 Feb; 12 (1):7-14
    View PubMed
  28. McKie PM, AbouEzzeddine OF, Scott CG, Mehta R, Rodeheffer RJ, Redfield MM, Burnett JC Jr, Jaffe AS. High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. Clin Chem. 2014 Sep; 60 (9):1225-33 Epub 2014 July 01
    View PubMed
  29. McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014 Jan 2; 3 (1):e000206 Epub 2014 Jan 02
    View PubMed
  30. Sangaralingham SJ, Burnett JC Jr, McKie PM, Schirger JA, Chen HH. Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction. J Card Fail. 2013 Aug; 19 (8):533-9
    View PubMed
  31. McKie PM, Heublein DM, Scott CG, Gantzer ML, Mehta RA, Rodeheffer RJ, Redfield MM, Burnett JC Jr, Jaffe AS. Defining high-sensitivity cardiac troponin concentrations in the community. Clin Chem. 2013 Jul; 59 (7):1099-107 Epub 2013 Apr 16
    View PubMed
  32. Geske JB, McKie PM, Ommen SR, Sorajja P. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Jun 18; 61 (24):2456-2460 Epub 2013 Apr 16
    View PubMed
  33. Ichiki T, Boerrigter G, Huntley BK, Sangaralingham SJ, McKie PM, Harty GJ, Harders GE, Burnett JC Jr. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15; 304 (2):R102-9 Epub 2012 Nov 14
    View PubMed
  34. McKie PM, McCully RB, Kamath PS, Bower TC, McKusick MA, Lapyere AC, Pereira NL. Amelioration of high cardiac output and pulmonary hypertension by occlusion of congenital porto-systemic shunt. Circulation. 2012 Nov 20; 126(21):2533-4.
    View PubMed
  35. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J Jr, Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012 Oct 16; 60 (16):1558-65
    View PubMed
  36. Sangaralingham SJ, Ritman EL, McKie PM, Ichiki T, Lerman A, Scott CG, Martin FL, Harders GE, Bellavia D, Burnett JC Jr. Cardiac micro-computed tomography imaging of the aging coronary vasculature. Circ Cardiovasc Imaging. 2012 Jul; 5 (4):518-24 Epub 2012 June 07
    View PubMed
  37. McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012 Feb; 14 (1):62-9
    View PubMed
  38. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15; 302 (2):R292-9 Epub 2011 Nov 09
    View PubMed
  39. Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders GE, Burnett JC Jr. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012; 7 (12):e52422 Epub 2012 Dec 18
    View PubMed
  40. McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011 Dec; 86 (12):1154-60
    View PubMed
  41. McKie PM, Schirger JA, Costello-Boerrigter LC, Benike SL, Harstad LK, Bailey KR, Hodge DO, Redfield MM, Simari RD, Burnett JC Jr, Chen HH. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011 Nov 8; 58 (20):2095-103
    View PubMed
  42. Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC Jr. Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. Am J Physiol Renal Physiol. 2011 Nov; 301 (5):F943-52 Epub 2011 Aug 24
    View PubMed
  43. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC Jr. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011 Aug 2; 58 (6):629-36
    View PubMed
  44. Macheret F, Boerrigter G, McKie P, Costello-Boerrigter L, Lahr B, Heublein D, Sandberg S, Ikeda Y, Cataliotti A, Bailey K, Rodeheffer R, Burnett JC Jr. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011 Mar 22; 57 (12):1386-95
    View PubMed
  45. Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC Jr. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension. 2011 Feb; 57 (2):201-7 Epub 2010 Dec 28
    View PubMed
  46. Ichiki T, Huntley BK, Heublein DM, Sandberg SM, McKie PM, Martin FL, Jougasaki M, Burnett JC Jr. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem. 2011 Jan; 57 (1):40-7 Epub 2010 Nov 12
    View PubMed
  47. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC Jr. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010 Dec; 56 (6):1152-9 Epub 2010 Oct 25
    View PubMed
  48. McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep. 2010 Sep; 7 (3):93-9
    View PubMed
  49. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010 May 11; 55 (19):2140-7
    View PubMed
  50. McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009 Sep 8; 54 (11):1024-32
    View PubMed
  51. Belluardo P, Cataliotti A, Bonaiuto L, Giuffre E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006 Oct; 291(4):H1529-35. Epub 2006 Apr 28.
    View PubMed
  52. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006 May; 47 (5):874-80 Epub 2006 Apr 03
    View PubMed
  53. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation. 2005 Aug 9; 112(6):836-40. Epub 2005 Aug 01.
    View PubMed
  54. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005 Aug; 80 (8):1029-36
    View PubMed
PST-20216714